Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
Event Held Today, October 11, 2018 CORALVILLE, Iowa , Oct. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided highlights from its investor event featuring a discussion with
Toggle Summary KemPharm Announces Pricing of Public Offering of Common Stock
CORALVILLE, Iowa , Oct. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of its underwritten public offering of 8,333,334 shares of its common stock at a price
Toggle Summary KemPharm Announces Proposed Public Offering of Common Stock
CORALVILLE, Iowa , Oct. 04, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. 
Toggle Summary KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape
Event to be Webcast Live on Thursday, October 11, 2018 , at 8:30 a.m. ET CORALVILLE, Iowa , Oct. 03, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will host an
Toggle Summary KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug
NDA Filing for KP415 Anticipated As Soon As First Quarter of 2019 Following Successful Completion of HAP Program d-MPH = d-methylphenidate hydrochloride. Drug Liking was assessed on a bipolar scale. (0 = Strong Disliking, 50 = Neutral, 100 = Strong Liking).
Toggle Summary KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
Highlights of KP415.A01 Oral HAP Trial Results: Oral Human Abuse Potential Trial with KP415 Prodrug (KP415.A01) Clinical Findings Mean Drug Liking (E max ) of KP415 Prodrug (serdexmethylphenidate) at both 120 mg and 240 mg doses were statistically significantly lower than Focalin ® XR at 80 mg Mean
Toggle Summary KemPharm to Present at Two Healthcare Investor Conferences During September 2018
CORALVILLE, Iowa , Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C.
Toggle Summary KemPharm, Inc. Reports Second Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced top line results from KP415.E01 efficacy and safety trial in children with ADHD Announced top line results from intravenous human abuse potential trial with KP415
Toggle Summary KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference
CORALVILLE, Iowa , Aug. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
Toggle Summary KemPharm, Inc. to Report Second Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  August 9, 2018 , 4:30 p.m. ET CORALVILLE, Iowa , July 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today